Alvespimycin is a potent inhibitor of Hsp90, binding to Hsp90 with an EC50 of 62 nM. Alvespimycin (17-DMAG) inhibits the growth of the human cancer cell lines SKBR3 and SKOV3, which overexpress Hsp90 client protein Her2, and causes down-regulation of Her2 as well as induction of Hsp70 consistent with Hsp90 inhibition, for Her2 degradation with EC50 of 8 ± 4 nM and 46 ± 24 nM in SKBR3 and SKOV3 cells, respectively; for Hsp70 induction with EC50 of 4 ± 2 nM and 14 ± 7 nM in SKBR3 and SKOV3 cells, respectively. Compared with the vehicle control, Alvespimycin dose-dependent apoptosis (P<0.001 averaged across 24- and 48-hour time points) at concentrations of 50 nM to 500 nM, which represent pharmacologically attainable doses. Similar to many other agents, Alvespimycin also demonstrates time-dependent apoptosis (P <0.001, averaged across all doses) in chronic lymphocytic leukemia (CLL) cells with extended exposure from 24 to 48 hours. In addition, Alvespimycin is much more potent after 24 and 48 hours of treatment than 17-AAG.
HSP (HSP90) inhibitor Related Prodcuts:
Tanespimycin; Luminespib; Ganetespib; BIIB021; Onalespib; NVP-BEP800; SNX-2112; PF-04929113; KW-2478; XL888; Zelavespib (PU-H71); KRIBB11; VER-50589; Triptolide; NVP-HSP990; Dimethylenastron; Geldanamycin